The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.